World Clinical Drug
|
2024, 45(11): 1105-1116
• Recommendation •
Expert consensus on the clinical application of anti-GD2 antibody naxitamab in the treatment of neuroblastoma (2024 Version)
Full
Collaborative Group for Immunotherapy Clinical Practice in Neuroblastoma
Affiliations
Published: 2024-11-10
doi: 10.13683/j.wph.2024.11.001
Outline
神经母细胞瘤免疫治疗临床应用协作组.
抗GD2单抗那西妥单抗治疗神经母细胞瘤临床应用专家共识(2024年版).
世界临床药物,
2024
, 45
(11)
: 1105
-1116
.
DOI: 10.13683/j.wph.2024.11.001
Collaborative Group for Immunotherapy Clinical Practice in Neuroblastoma.
Expert consensus on the clinical application of anti-GD2 antibody naxitamab in the treatment of neuroblastoma (2024 Version)[J].
World Clinical Drug,
2024
, 45
(11)
: 1105
-1116
.
DOI: 10.13683/j.wph.2024.11.001
Year 2024 volume 45 Issue 11
19
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.11.001
- Receive Date:2024-09-30
- Online Date:2026-11-17
- Published:2024-11-10